The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global GLP-1 Agonists for Obesity Market Research Report 2025
Synopsis
GLP-1 (glucagon-like peptide-1) agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists have been approved to help treat obesity. GLP-1 agonists have been shown to be effective in promoting weight loss in preclinical and clinical studies.
The global GLP-1 Agonists for Obesity market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for GLP-1 Agonists for Obesity is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for GLP-1 Agonists for Obesity is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of GLP-1 Agonists for Obesity include Novo Nordisk, Eli Lilly, Huadong Medicine, Shanghai Benemae Pharmaceutical Corporation, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for GLP-1 Agonists for Obesity, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GLP-1 Agonists for Obesity.
The GLP-1 Agonists for Obesity market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global GLP-1 Agonists for Obesity market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the GLP-1 Agonists for Obesity manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Novo Nordisk
Eli Lilly
Huadong Medicine
Shanghai Benemae Pharmaceutical Corporation
Segment by Type
Semaglutide
Tirzepatide
Liraglutide
Benaglutide
Segment by Application
Hospital Pharmaty
Retail Pharmaty
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of GLP-1 Agonists for Obesity manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of GLP-1 Agonists for Obesity in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
GLP-1 (glucagon-like peptide-1) agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with Type 2 diabetes. Some GLP-1 agonists have been approved to help treat obesity. GLP-1 agonists have been shown to be effective in promoting weight loss in preclinical and clinical studies.
The global GLP-1 Agonists for Obesity market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for GLP-1 Agonists for Obesity is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for GLP-1 Agonists for Obesity is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of GLP-1 Agonists for Obesity include Novo Nordisk, Eli Lilly, Huadong Medicine, Shanghai Benemae Pharmaceutical Corporation, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for GLP-1 Agonists for Obesity, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding GLP-1 Agonists for Obesity.
The GLP-1 Agonists for Obesity market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global GLP-1 Agonists for Obesity market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the GLP-1 Agonists for Obesity manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
By Company
Novo Nordisk
Eli Lilly
Huadong Medicine
Shanghai Benemae Pharmaceutical Corporation
Segment by Type
Semaglutide
Tirzepatide
Liraglutide
Benaglutide
Segment by Application
Hospital Pharmaty
Retail Pharmaty
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East and Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of GLP-1 Agonists for Obesity manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of GLP-1 Agonists for Obesity in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 GLP-1 Agonists for Obesity Market Overview
1.1 Product Definition
1.2 GLP-1 Agonists for Obesity by Type
1.2.1 Global GLP-1 Agonists for Obesity Market Value Comparison by Type (2024-2030)
1.2.2 Semaglutide
1.2.3 Tirzepatide
1.2.4 Liraglutide
1.2.5 Benaglutide
1.3 GLP-1 Agonists for Obesity by Application
1.3.1 Global GLP-1 Agonists for Obesity Market Value by Application (2024-2030)
1.3.2 Hospital Pharmaty
1.3.3 Retail Pharmaty
1.3.4 Others
1.4 Global GLP-1 Agonists for Obesity Market Size Estimates and Forecasts
1.4.1 Global GLP-1 Agonists for Obesity Revenue 2019-2030
1.4.2 Global GLP-1 Agonists for Obesity Sales 2019-2030
1.4.3 Global GLP-1 Agonists for Obesity Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 GLP-1 Agonists for Obesity Market Competition by Manufacturers
2.1 Global GLP-1 Agonists for Obesity Sales Market Share by Manufacturers (2019-2024)
2.2 Global GLP-1 Agonists for Obesity Revenue Market Share by Manufacturers (2019-2024)
2.3 Global GLP-1 Agonists for Obesity Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of GLP-1 Agonists for Obesity, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of GLP-1 Agonists for Obesity, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of GLP-1 Agonists for Obesity, Product Type & Application
2.7 Global Key Manufacturers of GLP-1 Agonists for Obesity, Date of Enter into This Industry
2.8 Global GLP-1 Agonists for Obesity Market Competitive Situation and Trends
2.8.1 Global GLP-1 Agonists for Obesity Market Concentration Rate
2.8.2 The Global 5 and 10 Largest GLP-1 Agonists for Obesity Players Market Share by Revenue
2.8.3 Global GLP-1 Agonists for Obesity Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global GLP-1 Agonists for Obesity Market Scenario by Region
3.1 Global GLP-1 Agonists for Obesity Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global GLP-1 Agonists for Obesity Sales by Region: 2019-2030
3.2.1 Global GLP-1 Agonists for Obesity Sales by Region: 2019-2024
3.2.2 Global GLP-1 Agonists for Obesity Sales by Region: 2025-2030
3.3 Global GLP-1 Agonists for Obesity Revenue by Region: 2019-2030
3.3.1 Global GLP-1 Agonists for Obesity Revenue by Region: 2019-2024
3.3.2 Global GLP-1 Agonists for Obesity Revenue by Region: 2025-2030
3.4 North America GLP-1 Agonists for Obesity Market Facts & Figures by Country
3.4.1 North America GLP-1 Agonists for Obesity Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America GLP-1 Agonists for Obesity Sales by Country (2019-2030)
3.4.3 North America GLP-1 Agonists for Obesity Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe GLP-1 Agonists for Obesity Market Facts & Figures by Country
3.5.1 Europe GLP-1 Agonists for Obesity Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe GLP-1 Agonists for Obesity Sales by Country (2019-2030)
3.5.3 Europe GLP-1 Agonists for Obesity Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific GLP-1 Agonists for Obesity Market Facts & Figures by Region
3.6.1 Asia Pacific GLP-1 Agonists for Obesity Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific GLP-1 Agonists for Obesity Sales by Region (2019-2030)
3.6.3 Asia Pacific GLP-1 Agonists for Obesity Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America GLP-1 Agonists for Obesity Market Facts & Figures by Country
3.7.1 Latin America GLP-1 Agonists for Obesity Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America GLP-1 Agonists for Obesity Sales by Country (2019-2030)
3.7.3 Latin America GLP-1 Agonists for Obesity Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa GLP-1 Agonists for Obesity Market Facts & Figures by Country
3.8.1 Middle East and Africa GLP-1 Agonists for Obesity Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa GLP-1 Agonists for Obesity Sales by Country (2019-2030)
3.8.3 Middle East and Africa GLP-1 Agonists for Obesity Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global GLP-1 Agonists for Obesity Sales by Type (2019-2030)
4.1.1 Global GLP-1 Agonists for Obesity Sales by Type (2019-2024)
4.1.2 Global GLP-1 Agonists for Obesity Sales by Type (2025-2030)
4.1.3 Global GLP-1 Agonists for Obesity Sales Market Share by Type (2019-2030)
4.2 Global GLP-1 Agonists for Obesity Revenue by Type (2019-2030)
4.2.1 Global GLP-1 Agonists for Obesity Revenue by Type (2019-2024)
4.2.2 Global GLP-1 Agonists for Obesity Revenue by Type (2025-2030)
4.2.3 Global GLP-1 Agonists for Obesity Revenue Market Share by Type (2019-2030)
4.3 Global GLP-1 Agonists for Obesity Price by Type (2019-2030)
5 Segment by Application
5.1 Global GLP-1 Agonists for Obesity Sales by Application (2019-2030)
5.1.1 Global GLP-1 Agonists for Obesity Sales by Application (2019-2024)
5.1.2 Global GLP-1 Agonists for Obesity Sales by Application (2025-2030)
5.1.3 Global GLP-1 Agonists for Obesity Sales Market Share by Application (2019-2030)
5.2 Global GLP-1 Agonists for Obesity Revenue by Application (2019-2030)
5.2.1 Global GLP-1 Agonists for Obesity Revenue by Application (2019-2024)
5.2.2 Global GLP-1 Agonists for Obesity Revenue by Application (2025-2030)
5.2.3 Global GLP-1 Agonists for Obesity Revenue Market Share by Application (2019-2030)
5.3 Global GLP-1 Agonists for Obesity Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novo Nordisk
6.1.1 Novo Nordisk Company Information
6.1.2 Novo Nordisk Description and Business Overview
6.1.3 Novo Nordisk GLP-1 Agonists for Obesity Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novo Nordisk GLP-1 Agonists for Obesity Product Portfolio
6.1.5 Novo Nordisk Recent Developments/Updates
6.2 Eli Lilly
6.2.1 Eli Lilly Company Information
6.2.2 Eli Lilly Description and Business Overview
6.2.3 Eli Lilly GLP-1 Agonists for Obesity Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Eli Lilly GLP-1 Agonists for Obesity Product Portfolio
6.2.5 Eli Lilly Recent Developments/Updates
6.3 Huadong Medicine
6.3.1 Huadong Medicine Company Information
6.3.2 Huadong Medicine Description and Business Overview
6.3.3 Huadong Medicine GLP-1 Agonists for Obesity Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Huadong Medicine GLP-1 Agonists for Obesity Product Portfolio
6.3.5 Huadong Medicine Recent Developments/Updates
6.4 Shanghai Benemae Pharmaceutical Corporation
6.4.1 Shanghai Benemae Pharmaceutical Corporation Company Information
6.4.2 Shanghai Benemae Pharmaceutical Corporation Description and Business Overview
6.4.3 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Product Portfolio
6.4.5 Shanghai Benemae Pharmaceutical Corporation Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 GLP-1 Agonists for Obesity Industry Chain Analysis
7.2 GLP-1 Agonists for Obesity Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 GLP-1 Agonists for Obesity Production Mode & Process
7.4 GLP-1 Agonists for Obesity Sales and Marketing
7.4.1 GLP-1 Agonists for Obesity Sales Channels
7.4.2 GLP-1 Agonists for Obesity Distributors
7.5 GLP-1 Agonists for Obesity Customers
8 GLP-1 Agonists for Obesity Market Dynamics
8.1 GLP-1 Agonists for Obesity Industry Trends
8.2 GLP-1 Agonists for Obesity Market Drivers
8.3 GLP-1 Agonists for Obesity Market Challenges
8.4 GLP-1 Agonists for Obesity Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global GLP-1 Agonists for Obesity Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global GLP-1 Agonists for Obesity Market Value by Application (2024-2030) & (US$ Million)
Table 3. Global GLP-1 Agonists for Obesity Market Competitive Situation by Manufacturers in 2023
Table 4. Global GLP-1 Agonists for Obesity Sales (K Dose) of Key Manufacturers (2019-2024)
Table 5. Global GLP-1 Agonists for Obesity Sales Market Share by Manufacturers (2019-2024)
Table 6. Global GLP-1 Agonists for Obesity Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global GLP-1 Agonists for Obesity Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market GLP-1 Agonists for Obesity Average Price (US$/Dose) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of GLP-1 Agonists for Obesity, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of GLP-1 Agonists for Obesity, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of GLP-1 Agonists for Obesity, Product Type & Application
Table 12. Global Key Manufacturers of GLP-1 Agonists for Obesity, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global GLP-1 Agonists for Obesity by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in GLP-1 Agonists for Obesity as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global GLP-1 Agonists for Obesity Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global GLP-1 Agonists for Obesity Sales by Region (2019-2024) & (K Dose)
Table 18. Global GLP-1 Agonists for Obesity Sales Market Share by Region (2019-2024)
Table 19. Global GLP-1 Agonists for Obesity Sales by Region (2025-2030) & (K Dose)
Table 20. Global GLP-1 Agonists for Obesity Sales Market Share by Region (2025-2030)
Table 21. Global GLP-1 Agonists for Obesity Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global GLP-1 Agonists for Obesity Revenue Market Share by Region (2019-2024)
Table 23. Global GLP-1 Agonists for Obesity Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global GLP-1 Agonists for Obesity Revenue Market Share by Region (2025-2030)
Table 25. North America GLP-1 Agonists for Obesity Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America GLP-1 Agonists for Obesity Sales by Country (2019-2024) & (K Dose)
Table 27. North America GLP-1 Agonists for Obesity Sales by Country (2025-2030) & (K Dose)
Table 28. North America GLP-1 Agonists for Obesity Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America GLP-1 Agonists for Obesity Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe GLP-1 Agonists for Obesity Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe GLP-1 Agonists for Obesity Sales by Country (2019-2024) & (K Dose)
Table 32. Europe GLP-1 Agonists for Obesity Sales by Country (2025-2030) & (K Dose)
Table 33. Europe GLP-1 Agonists for Obesity Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe GLP-1 Agonists for Obesity Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific GLP-1 Agonists for Obesity Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific GLP-1 Agonists for Obesity Sales by Region (2019-2024) & (K Dose)
Table 37. Asia Pacific GLP-1 Agonists for Obesity Sales by Region (2025-2030) & (K Dose)
Table 38. Asia Pacific GLP-1 Agonists for Obesity Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific GLP-1 Agonists for Obesity Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America GLP-1 Agonists for Obesity Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America GLP-1 Agonists for Obesity Sales by Country (2019-2024) & (K Dose)
Table 42. Latin America GLP-1 Agonists for Obesity Sales by Country (2025-2030) & (K Dose)
Table 43. Latin America GLP-1 Agonists for Obesity Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America GLP-1 Agonists for Obesity Revenue Market Share by Country (2019-2024)
Table 45. Middle East and Africa GLP-1 Agonists for Obesity Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East and Africa GLP-1 Agonists for Obesity Sales by Country (2019-2024) & (K Dose)
Table 47. Middle East and Africa GLP-1 Agonists for Obesity Sales by Country (2025-2030) & (K Dose)
Table 48. Middle East and Africa GLP-1 Agonists for Obesity Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East and Africa GLP-1 Agonists for Obesity Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global GLP-1 Agonists for Obesity Sales (K Dose) by Type (2019-2024)
Table 51. Global GLP-1 Agonists for Obesity Sales (K Dose) by Type (2025-2030)
Table 52. Global GLP-1 Agonists for Obesity Sales Market Share by Type (2019-2024)
Table 53. Global GLP-1 Agonists for Obesity Sales Market Share by Type (2025-2030)
Table 54. Global GLP-1 Agonists for Obesity Revenue (US$ Million) by Type (2019-2024)
Table 55. Global GLP-1 Agonists for Obesity Revenue (US$ Million) by Type (2025-2030)
Table 56. Global GLP-1 Agonists for Obesity Revenue Market Share by Type (2019-2024)
Table 57. Global GLP-1 Agonists for Obesity Revenue Market Share by Type (2025-2030)
Table 58. Global GLP-1 Agonists for Obesity Price (US$/Dose) by Type (2019-2024)
Table 59. Global GLP-1 Agonists for Obesity Price (US$/Dose) by Type (2025-2030)
Table 60. Global GLP-1 Agonists for Obesity Sales (K Dose) by Application (2019-2024)
Table 61. Global GLP-1 Agonists for Obesity Sales (K Dose) by Application (2025-2030)
Table 62. Global GLP-1 Agonists for Obesity Sales Market Share by Application (2019-2024)
Table 63. Global GLP-1 Agonists for Obesity Sales Market Share by Application (2025-2030)
Table 64. Global GLP-1 Agonists for Obesity Revenue (US$ Million) by Application (2019-2024)
Table 65. Global GLP-1 Agonists for Obesity Revenue (US$ Million) by Application (2025-2030)
Table 66. Global GLP-1 Agonists for Obesity Revenue Market Share by Application (2019-2024)
Table 67. Global GLP-1 Agonists for Obesity Revenue Market Share by Application (2025-2030)
Table 68. Global GLP-1 Agonists for Obesity Price (US$/Dose) by Application (2019-2024)
Table 69. Global GLP-1 Agonists for Obesity Price (US$/Dose) by Application (2025-2030)
Table 70. Novo Nordisk Company Information
Table 71. Novo Nordisk Description and Business Overview
Table 72. Novo Nordisk GLP-1 Agonists for Obesity Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 73. Novo Nordisk GLP-1 Agonists for Obesity Product
Table 74. Novo Nordisk Recent Developments/Updates
Table 75. Eli Lilly Company Information
Table 76. Eli Lilly Description and Business Overview
Table 77. Eli Lilly GLP-1 Agonists for Obesity Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 78. Eli Lilly GLP-1 Agonists for Obesity Product
Table 79. Eli Lilly Recent Developments/Updates
Table 80. Huadong Medicine Company Information
Table 81. Huadong Medicine Description and Business Overview
Table 82. Huadong Medicine GLP-1 Agonists for Obesity Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 83. Huadong Medicine GLP-1 Agonists for Obesity Product
Table 84. Huadong Medicine Recent Developments/Updates
Table 85. Shanghai Benemae Pharmaceutical Corporation Company Information
Table 86. Shanghai Benemae Pharmaceutical Corporation Description and Business Overview
Table 87. Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 88. Shanghai Benemae Pharmaceutical Corporation GLP-1 Agonists for Obesity Product
Table 89. Shanghai Benemae Pharmaceutical Corporation Recent Developments/Updates
Table 90. Key Raw Materials Lists
Table 91. Raw Materials Key Suppliers Lists
Table 92. GLP-1 Agonists for Obesity Distributors List
Table 93. GLP-1 Agonists for Obesity Customers List
Table 94. GLP-1 Agonists for Obesity Market Trends
Table 95. GLP-1 Agonists for Obesity Market Drivers
Table 96. GLP-1 Agonists for Obesity Market Challenges
Table 97. GLP-1 Agonists for Obesity Market Restraints
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
Table 101. Authors List of This Report
List of Figures
Figure 1. Product Picture of GLP-1 Agonists for Obesity
Figure 2. Global GLP-1 Agonists for Obesity Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global GLP-1 Agonists for Obesity Market Share by Type: 2023 & 2030
Figure 4. Semaglutide Product Picture
Figure 5. Tirzepatide Product Picture
Figure 6. Liraglutide Product Picture
Figure 7. Benaglutide Product Picture
Figure 8. Global GLP-1 Agonists for Obesity Market Value by Application (2024-2030) & (US$ Million)
Figure 9. Global GLP-1 Agonists for Obesity Market Share by Application: 2023 & 2030
Figure 10. Hospital Pharmaty
Figure 11. Retail Pharmaty
Figure 12. Others
Figure 13. Global GLP-1 Agonists for Obesity Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global GLP-1 Agonists for Obesity Market Size (2019-2030) & (US$ Million)
Figure 15. Global GLP-1 Agonists for Obesity Sales (2019-2030) & (K Dose)
Figure 16. Global GLP-1 Agonists for Obesity Average Price (US$/Dose) & (2019-2030)
Figure 17. GLP-1 Agonists for Obesity Report Years Considered
Figure 18. GLP-1 Agonists for Obesity Sales Share by Manufacturers in 2023
Figure 19. Global GLP-1 Agonists for Obesity Revenue Share by Manufacturers in 2023
Figure 20. Global 5 and 10 Largest GLP-1 Agonists for Obesity Players: Market Share by Revenue in GLP-1 Agonists for Obesity in 2023
Figure 21. GLP-1 Agonists for Obesity Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 22. Global GLP-1 Agonists for Obesity Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 23. North America GLP-1 Agonists for Obesity Sales Market Share by Country (2019-2030)
Figure 24. North America GLP-1 Agonists for Obesity Revenue Market Share by Country (2019-2030)
Figure 25. United States GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Canada GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Europe GLP-1 Agonists for Obesity Sales Market Share by Country (2019-2030)
Figure 28. Europe GLP-1 Agonists for Obesity Revenue Market Share by Country (2019-2030)
Figure 29. Germany GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. France GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. U.K. GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Italy GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Russia GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Asia Pacific GLP-1 Agonists for Obesity Sales Market Share by Region (2019-2030)
Figure 35. Asia Pacific GLP-1 Agonists for Obesity Revenue Market Share by Region (2019-2030)
Figure 36. China GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Japan GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. South Korea GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. India GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Australia GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. China Taiwan GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Southeast Asia GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Latin America GLP-1 Agonists for Obesity Sales Market Share by Country (2019-2030)
Figure 44. Mexico GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Brazil GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Argentina GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Colombia GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Middle East and Africa GLP-1 Agonists for Obesity Sales Market Share by Country (2019-2030)
Figure 49. Middle East and Africa GLP-1 Agonists for Obesity Revenue Market Share by Country (2019-2030)
Figure 50. Turkey GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. UAE GLP-1 Agonists for Obesity Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Global Sales Market Share of GLP-1 Agonists for Obesity by Type (2019-2030)
Figure 54. Global Revenue Market Share of GLP-1 Agonists for Obesity by Type (2019-2030)
Figure 55. Global GLP-1 Agonists for Obesity Price (US$/Dose) by Type (2019-2030)
Figure 56. Global Sales Market Share of GLP-1 Agonists for Obesity by Application (2019-2030)
Figure 57. Global Revenue Market Share of GLP-1 Agonists for Obesity by Application (2019-2030)
Figure 58. Global GLP-1 Agonists for Obesity Price (US$/Dose) by Application (2019-2030)
Figure 59. GLP-1 Agonists for Obesity Value Chain
Figure 60. GLP-1 Agonists for Obesity Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
